A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer

Conditions

English First-line extensive-stage small-cell lung cancer (ES-SCLC)

Brief summary

Overall survival (OS) defined as the time from randomization to death from any cause.

Detailed description

Progression-free survival (PFS) defined as the time from randomization to first objective tumor progression, or death from any cause, whichever occurs first., Objective response rate (ORR) defined as the proportion of participants in whom a complete response (CR) or partial response (PR) is observed as best overall response with confirmation., Duration of response (DOR) defined as the time from onset of objective response (confirmed CR or PR based on investigator’s assessment) to first occurrence of objective tumor progression (progressive disease) or death from any cause, whichever occurs first., Progression-free survival (PFS) rate based on investigator’s assessment at 6, 12, and 18 months., Overall survival (OS) rate at 6, 12, 18, and 24 months., Occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs, by relationship., Occurrence of dose delay, infusion interruption, and discontinuation of study treatment due to TEAEs (including related TEAEs), Change from baseline in EORTC QLQ-C30 Global Health status / Quality-of-Life score (Items 29 and 30)., Change from baseline in EORTC QLQ-C30 physical functioning, Change from baseline in coughing scale of the EORTC quality-of-life-Lung cancer 29 questionnaire (QLQ-LC29)., Change from baseline in shortness of breath scale of the EORTC QLQ-LC29., Change from baseline in "coughed up blood item" of the EORTC QLQ-LC29, Change from baseline in the Functional Assessment of Cancer Therapy overall bother item (FACT-GP5).

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGCARBOPLATIN

DRUGCISPLATIN

DRUGETOPOSIDE

DRUGBNT327

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) defined as the time from randomization to death from any cause.	—

Secondary

Measure	Time frame
Progression-free survival (PFS) defined as the time from randomization to first objective tumor progression, or death from any cause, whichever occurs first., Objective response rate (ORR) defined as the proportion of participants in whom a complete response (CR) or partial response (PR) is observed as best overall response with confirmation., Duration of response (DOR) defined as the time from onset of objective response (confirmed CR or PR based on investigator’s assessment) to first occurrence of objective tumor progression (progressive disease) or death from any cause, whichever occurs first., Progression-free survival (PFS) rate based on investigator’s assessment at 6, 12, and 18 months., Overall survival (OS) rate at 6, 12, 18, and 24 months., Occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs, by relationship., Occurrence of dose delay, infusion interruption, and discontinuation of study treatment due to TEAEs (including related	—

Measure

Time frame

Progression-free survival (PFS) defined as the time from randomization to first objective tumor progression, or death from any cause, whichever occurs first., Objective response rate (ORR) defined as the proportion of participants in whom a complete response (CR) or partial response (PR) is observed as best overall response with confirmation., Duration of response (DOR) defined as the time from onset of objective response (confirmed CR or PR based on investigator’s assessment) to first occurrence of objective tumor progression (progressive disease) or death from any cause, whichever occurs first., Progression-free survival (PFS) rate based on investigator’s assessment at 6, 12, and 18 months., Overall survival (OS) rate at 6, 12, 18, and 24 months., Occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥3, serious, and fatal TEAEs, by relationship., Occurrence of dose delay, infusion interruption, and discontinuation of study treatment due to TEAEs (including related

—

Countries

France, Germany, Italy, Poland, Spain

Outcome results

None listed